Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma
While outcomes for pediatric acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) have improved dramatically in recent decades, relapsed and refractory disease remain a significant therapeutic challenge. This is particularly true for patients with T-cell ALL and LBL, where survival f...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-01-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11894 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841550915781263360 |
|---|---|
| author | Andrew D. Hughes Petri Pölönen David T. Teachey |
| author_facet | Andrew D. Hughes Petri Pölönen David T. Teachey |
| author_sort | Andrew D. Hughes |
| collection | DOAJ |
| description |
While outcomes for pediatric acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) have improved dramatically in recent decades, relapsed and refractory disease remain a significant therapeutic challenge. This is particularly true for patients with T-cell ALL and LBL, where survival for patients with relapsed/refractory disease remains dismal. Recent efforts to comprehensively profile the genomics of T-ALL/LBL to improve understanding of disease biology have enhanced our ability to identify high-risk patients at diagnosis who are more likely to relapse and have also identified novel targets for precision medicines. Novel immunotherapies have transformed the treatment landscape for patients with B-cell ALL (B-ALL). Many immunotherapies are under investigation in clinical trials for patients with T-ALL/LBL and early results are very promising. Given these insights into disease biology and the development of targeted and immune-based treatments, it is reasonable to hope for improved patient outcomes, although challenges still exist. In this review, we summarize the present state of understanding of the risk factors for relapse of T-ALL/LBL, established treatment regimens, and the promising small molecule inhibitors and immunotherapies with the potential to revolutionize the treatment of relapsed/refractory T-ALL/LBL.
|
| format | Article |
| id | doaj-art-681afcda9c9b4c5d94af080fc9639027 |
| institution | Kabale University |
| issn | 0390-6078 1592-8721 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Ferrata Storti Foundation |
| record_format | Article |
| series | Haematologica |
| spelling | doaj-art-681afcda9c9b4c5d94af080fc96390272025-01-09T19:43:53ZengFerrata Storti FoundationHaematologica0390-60781592-87212025-01-01999110.3324/haematol.2024.285643Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphomaAndrew D. Hughes0Petri Pölönen1David T. Teachey2Division of Oncology, the Children’s Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, the University of Pennsylvania Perelman School of Medicine, Philadelphia, PADepartment of Pathology, St. Jude Children’s Research Hospital, Memphis, TNDivision of Oncology, the Children’s Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA While outcomes for pediatric acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) have improved dramatically in recent decades, relapsed and refractory disease remain a significant therapeutic challenge. This is particularly true for patients with T-cell ALL and LBL, where survival for patients with relapsed/refractory disease remains dismal. Recent efforts to comprehensively profile the genomics of T-ALL/LBL to improve understanding of disease biology have enhanced our ability to identify high-risk patients at diagnosis who are more likely to relapse and have also identified novel targets for precision medicines. Novel immunotherapies have transformed the treatment landscape for patients with B-cell ALL (B-ALL). Many immunotherapies are under investigation in clinical trials for patients with T-ALL/LBL and early results are very promising. Given these insights into disease biology and the development of targeted and immune-based treatments, it is reasonable to hope for improved patient outcomes, although challenges still exist. In this review, we summarize the present state of understanding of the risk factors for relapse of T-ALL/LBL, established treatment regimens, and the promising small molecule inhibitors and immunotherapies with the potential to revolutionize the treatment of relapsed/refractory T-ALL/LBL. https://haematologica.org/article/view/11894 |
| spellingShingle | Andrew D. Hughes Petri Pölönen David T. Teachey Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma Haematologica |
| title | Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma |
| title_full | Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma |
| title_fullStr | Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma |
| title_full_unstemmed | Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma |
| title_short | Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma |
| title_sort | relapsed childhood t cell acute lymphoblastic leukemia and lymphoblastic lymphoma |
| url | https://haematologica.org/article/view/11894 |
| work_keys_str_mv | AT andrewdhughes relapsedchildhoodtcellacutelymphoblasticleukemiaandlymphoblasticlymphoma AT petripolonen relapsedchildhoodtcellacutelymphoblasticleukemiaandlymphoblasticlymphoma AT davidtteachey relapsedchildhoodtcellacutelymphoblasticleukemiaandlymphoblasticlymphoma |